Probucol alleviates atherosclerosis and improves high density lipoprotein function

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Zhong, Jian Kai ^a   Guo, Zhi Gang ^a   Li, Chen ^a   Wang, Zhen Kun ^a   Lai, Wen Yan ^a   Tu, Yan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

high density lipoprotein function; Myeloperoxidase; Paraoxonase 1; probucol; reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; MYELOPEROXIDASE; PROBUCOL; ABC TRANSPORTER; ARYLDIALKYLPHOSPHATASE; CD36 ANTIGEN; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; PEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; LIPID DIET; LIVER CELL; MALE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RABBIT; ANIMAL; AORTA; ATHEROSCLEROSIS; BLOOD; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION; GENETICS; INTIMA; LIVER; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SECRETION; UPREGULATION;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIGENS, CD36; AORTA; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; CHOLESTEROL; DIET, HIGH-FAT; GENE EXPRESSION; HEPATOCYTES; LIPOPROTEINS, HDL; LIVER; MACROPHAGES, PERITONEAL; MALE; PEROXIDASE; PROBUCOL; RABBITS; RANDOM ALLOCATION; TUNICA INTIMA; UP-REGULATION;

EID: 81055138799     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-210     Document Type: Article

References (38)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Circulation 2002 106 3143 3421 12485966
2. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Franceschini G, Am J Cardiol 2001 88 12 9N 13N 10.1016/S0002-9149(01)02146-4 11788124 (Pubitemid 34088190)
3. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I (Milano) mutant. Gomaraschi M, Baldassarre D, Amato M, Eligini S, Conca P, Sirtori CR, Franceschini G, Calabresi L, Circulation 2007 116 2165 2172 10.1161/CIRCULATIONAHA.107.705657 17967773 (Pubitemid 350060354)
4. Effects of Torcetrapib in Patients at High Risk for Coronary Events. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Sendon JL, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, N Engl J Med 2007 357 2109 2122 10.1056/NEJMoa0706628 17984165 (Pubitemid 350146106)
5. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Hausenloy DJ, Yellon DM, Postgrad Med J 2008 84 997 590 598 19103817
6. Where are we with probucol: a new life for an old drug? Yamashita S, Matsuzawa Y, Atherosclerosis 2009 207 1 16 23 10.1016/j.atherosclerosis.2009.04. 002 19457483
7. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, Guise P, N Engl J Med 1997 337 365 732 10.1056/NEJM199708073370601 9241125 (Pubitemid 27328366)
8. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y, J Atheroscler Thromb 2008 15 6 292 303 10.5551/jat.E610 19060422
9. HDL structure, function, therapeutics, and imaging. Hazen S, Arterioscler Thromb Vasc Biol 2010 30 2 138 10.1161/ATVBAHA.109.201897 20089949
10. HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE, Atherosclerosis 2010 208 1 3 9 10.1016/j.atherosclerosis.2009.05.034 19595353
11. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, Zeljkovic A, Stefanovic A, Zunic G, Eur J Clin Invest 2007 37 9 715 723 10.1111/j.1365-2362.2007.01849.x 17696961 (Pubitemid 47256172)
12. The role of myeloperoxidase in HDL oxidation and atherogenesis. Heinecke JW, Curr Atheroscler Rep 2007 9 4 249 251 10.1007/s11883-007-0027-2 18173946 (Pubitemid 350081468)
13. Update on strategies to increase HDL quantity and function. Duffy D, Rader DJ, Nat Rev Cardiol 2009 6 7 455 463 10.1038/nrcardio.2009.94 19488077
14. Laboratory assessment of HDL heterogeneity and function. Movva R, Rader DJ, Ann Biol Clin (Paris) 2009 67 1 7 21
15. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Kontush A, Chapman MJ, Pharmacol Rev 2006 58 3 342 374 10.1124/pr.58.3.1 16968945 (Pubitemid 44394906)
16. Laboratory assessment of HDL heterogeneity and function. Movva R, Rader DJ, Ann Biol Clin (Paris) 2009 67 1 7 21
17. Latest Insights into High Density Lipoprotein Functions. Hiroshi N, The Endocrinologist 2009 19 4 179 186 10.1097/TEN.0b013e3181a6a5ed
18. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Orsá E, Broccardo C, Kaminski WE, Böttcher A, Liebisch G, Drobnik W, Götz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani MF, Rothe G, Lackner KJ, Chimini G, Schmitz G, Nat Genet 2000 24 2 192 196 10.1038/72869 10655069 (Pubitemid 30094724)
19. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. Neufeld EB, Stonik JA, Demosky SJ Jr, Knapper CL, Combs CA, Cooney A, Comly M, Dwyer N, Blanchette-Mackie J, Remaley AT, Santamarina-Fojo S, Brewer HB Jr, J Biol Chem 2004 279 15 15571 15578 10.1074/jbc.M314160200 14747463 (Pubitemid 38618958)
20. Regulation and activity of the human ABCA1 gene in transgenic mice. Cavelier LB, Qiu Y, Bielicki JK, Afzal V, Cheng JF, Rubin EM, J Biol Chem 2001 276 21 18046 18051 10.1074/jbc.M100565200 11279093
21. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. Zannis VI, Chroni A, Krieger M, J Mol Med 2006 84 4 276 294 10.1007/s00109-005-0030-4 16501936
22. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. Liadaki KN, Liu T, Xu S, Ishida BY, Duchateaux PN, Krieger JP, Kane J, Krieger M, Zannis VI, J Biol Chem 2000 275 28 21262 21271 10.1074/jbc.M002310200 10801839 (Pubitemid 30481823)
23. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M, Proc Natl Acad Sci USA 1997 94 23 12610 12615 10.1073/pnas.94.23. 12610 9356497 (Pubitemid 27492576)
24. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. Out R, Hoekstra M, Spijkers JA, Kruijt JK, van Eck M, Bos IS, Twisk J, Van Berkel TJ, J Lipid Res 2004 45 11 2088 2095 10.1194/jlr.M400191-JLR200 15314100 (Pubitemid 40990903)
25. HDL, its enzymes and its potential to influence lipid peroxidation. Mackness MI, Durrington PN, Atherosclerosis 1995 115 2 243 253 10.1016/0021-9150(94)05524-M 7661883
26. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Kontush A, Chantepie S, Chapman MJ, Arterioscler Thromb Vasc Biol 2003 23 10 1881 1888 10.1161/01.ATV.0000091338.93223.E8 12920049 (Pubitemid 37254879)
27. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI, Eur J Clin Invest 2002 32 4 259 264 10.1046/j.1365-2362.2002.00977.x 11952811 (Pubitemid 36216591)
28. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM, La Du BN, J Clin Invest 1997 99 8 2005 2019 10.1172/JCI119369 9109446 (Pubitemid 27175949)
29. Remodelling of high density lipoproteins by plasma factors. Rye KA, Clay MA, Barter PJ, Atherosclerosis 1999 145 2 227 238 10.1016/S0021-9150(99)00150-1 10488948 (Pubitemid 29359129)
30. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. K Nicholls SJ, Zheng L, Hazen SL, Trends Cardiovasc Med 2005 15 6 212 219 10.1016/j.tcm.2005.06.004 16182131 (Pubitemid 41338008)
31. Coexistence of oxidized lipids and alpha-tocopherol in all lipoprotein density fractions isolated from advanced human atherosclerotic plaques. Niu X, Zammit V, Upston JM, Dean RT, Stocker R, Arterioscler Thromb Vasc Biol 1999 19 7 1708 1718 10.1161/01.ATV.19.7.1708 10397689 (Pubitemid 29323830)
32. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL, J Clin Invest 2004 114 4 529 541 15314690 (Pubitemid 39572103)
33. Differential effect of antioxidant treatment on plasma and tissue paraoxonase activity in hyperleptinemic rats. Beltowski J, Jamroz-Wisniewska A, Borkowska E, Wájcicka G, Pharmacol Res 2005 51 6 523 532 10.1016/j.phrs.2005.01.007 15829432
34. Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Zhao SP, Yang J, Li J, Dong SZ, Wu ZH, Int J Cardiol 2008 124 2 172 178 10.1016/j.ijcard.2006. 12.032 17395297 (Pubitemid 351173356)
35. An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma. Troutt JS, Alborn WE, Mosior MK, Dai J, Murphy AT, Beyer TP, Zhang Y, Cao G, Konrad RJ, J Lipid Res 2008 49 3 581 587 10.1194/jlr.M700385-JLR200 18056684
36. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 4 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
37. 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages. Pirillo A, Uboldi P, Kuhn H, Catapano AL, Biochim Biophys Acta 2006 1761 3 292 300 10.1016/j.bbalip.2006.03.009 16647293
38. Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Speidl WS, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia MJ, Fuster V, Goldman ME, Badimon JJ, Eur Heart J 2010 31 16 2049 2057 20304838